Universitätsklinik Tübingen
Welcome,         Profile    Billing    Logout  
 24 Trials 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Müller, Arndt-Christian
M-basePro, NCT02724670: Study of MR-based IGRT for Prostate Cancer

Recruiting
2
78
Europe
IGRT
University Hospital Tuebingen
Prostate Cancer
06/20
09/28
NCT04159051: Charité HT-Prostate

Recruiting
2
100
Europe
Regional Hyperthermia
Charite University, Berlin, Germany
Prostate Cancer, Recurrence
01/21
01/24
SAKK 01/18, NCT03937843 / 2019-000514-11: Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Active, not recruiting
2
135
Europe
Carboplatin, Cisplatin, Etoposide
Swiss Group for Clinical Cancer Research, German Testicular Cancer Study Group
Seminoma, Testicular Cancer
12/26
12/46
Mbase_HyPro, NCT03880851: MR-based Hypofractionated Adaptive IGRT of Prostate Cancer (M-base HyPro 2.0)

Recruiting
N/A
78
Europe
Plan adaptation of Radiation Treatment in case of anatomical changes
University Hospital Tuebingen
Prostate Cancer
01/24
01/24
Gani, Cihan
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
CAO/ARO/AIO-16, NCT03561142: Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.

Recruiting
2
94
Europe
Radiotherapy, Chemotherapy, all brands of the used drugs are allowed, Deep regional hyperthermia
University Hospital Tuebingen
Rectal Cancer, Rectal Neoplasms, Rectal Cancer Stage II, Rectal Cancer Stage III
04/20
04/24
SAKK 16/18, NCT04245514: Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
90
Europe
Durvalumab, Radiotherapy
Swiss Group for Clinical Cancer Research
Non-small Cell Lung Cancer, NSCLC
12/25
12/31
RADIANCE, NCT04230759 / 2018-003005-25: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Active, not recruiting
2
180
Europe
Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor
Goethe University, German Cancer Aid, AstraZeneca
Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
12/26
03/27
NCT06385288: Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

Recruiting
N/A
30
Europe
Blood and tissue collection for immunological studies, advanced imaging., neoadjuvant Therapy
University Hospital Tuebingen
Soft Tissue Sarcoma Adult
07/26
07/31
MOMENTUM, NCT04075305: The Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Recruiting
N/A
8000
Europe, Canada, US, RoW
Radiation therapy
UMC Utrecht, The Netherlands Cancer Institute, Sunnybrook Health Sciences Centre, M.D. Anderson Cancer Center, The Christie NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Medical College of Wisconsin, Elekta Limited, Odense University Hospital, Radboud University Medical Center, Radiotherapiegroep, Jules Bordet Institute, University Hospital Tuebingen, Radiotherapeutic Institute Friesland, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), IRCCS Sacro Cuore Don Calabria di Negrar, Austin Health, Princess Margaret Hospital, Canada, Università degli Studi di Brescia
Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
02/24
05/25
OnkoFit I, NCT04506476: Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Adjuvant Radiotherapy of Breast Cancer

Recruiting
N/A
201
Europe
Fitness tracker based activity training for Arm A and B. Booklet "physical training, exercise and cancer" and an introduction about physical activity during cancer therapy for Arm A, B, C
University Hospital Tuebingen
Breast Cancer
08/24
08/25
OnkoFit II, NCT04517019: Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy

Recruiting
N/A
201
Europe
Fitness tracker based activity training for Arm A and B. Booklet "physical training, exercise and cancer" and an introduction about physical activity during cancer therapy for Arm A, B, C
University Hospital Tuebingen
Bronchial Carcinoma, Esophageal Carcinoma, Tumor of the Brain, Head and Neck Cancer, Pancreas Cancer, Sarcoma, Cervix Uteri Cancer
08/24
08/25
Zips, Daniel
RADIANCE, NCT04230759 / 2018-003005-25: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Active, not recruiting
2
180
Europe
Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor
Goethe University, German Cancer Aid, AstraZeneca
Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
12/26
03/27
HyRec, NCT01716949: Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer

Recruiting
1/2
59
Europe
Radiotherapy, Hyperthermia, 5-Fluorouracil, all brands of 5-Fluorouracil are allowed, Capecitabine, all brands of Capecitabine are allowed, Oxaliplatin, all brands of oxaliplatin are allowed
University of Erlangen-Nürnberg Medical School
Rectal Cancer
06/22
06/23
MR-Linac, NCT04172753: Feasibility of Online MR-guided Radiotherapy on a 1.5T

Recruiting
N/A
472
Europe
Radiotherapy on the MR-Linac, Imaging on the MR Linac
University Hospital Tuebingen
Rectal Cancer, Head and Neck Cancer, Liver Cancer, Breast Cancer, Prostate Cancer, Oligometastasis, Esophageal Cancer
05/22
05/27
OnkoFit I, NCT04506476: Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Adjuvant Radiotherapy of Breast Cancer

Recruiting
N/A
201
Europe
Fitness tracker based activity training for Arm A and B. Booklet "physical training, exercise and cancer" and an introduction about physical activity during cancer therapy for Arm A, B, C
University Hospital Tuebingen
Breast Cancer
08/24
08/25
OnkoFit II, NCT04517019: Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy

Recruiting
N/A
201
Europe
Fitness tracker based activity training for Arm A and B. Booklet "physical training, exercise and cancer" and an introduction about physical activity during cancer therapy for Arm A, B, C
University Hospital Tuebingen
Bronchial Carcinoma, Esophageal Carcinoma, Tumor of the Brain, Head and Neck Cancer, Pancreas Cancer, Sarcoma, Cervix Uteri Cancer
08/24
08/25
DELPHI, NCT03396718: De-escalation of Adjuvant Radio (chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas

Recruiting
N/A
304
Europe
De-escalation radio(chemo)therapy - Level 1, De-escalation radio(chemo)therapy - Level 2, Standard radio(chemotherapy)
Technische Universität Dresden, German Cancer Research Center, National Center for Tumor Diseases (NCT) Dresden, National Center for Tumor Diseases, Heidelberg, Radiation Oncology Working Group of the German Cancer Society
Head-and-neck Squamous Cell Carcinoma
11/29
11/32
Bedke, Jens
SAKK 01/10, NCT01593241 / 2011-005840-87: Therapy De-escalation in Seminoma Stage IIA/B

Active, not recruiting
2
115
Europe
Carboplatin, Involved node RT
Swiss Group for Clinical Cancer Research
Seminoma
12/24
09/38
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
Fallgatter, Andreas J
Ket+CBASP, NCT06410599 / 2019-001692-37: Pharmacologic Treatment Augmentation in Chronic Depression

Not yet recruiting
2
60
Europe
Ketamine, Ketamine hydrochloride (Ketamin Inresa 2 ml), Placebo, Saline solution: Fresenius Kabi Deutschland GmbH Isotone E NaCL 0.9 %, CBASP, Cognitive Behavioral Analysis System of Psychotherapy, TAU, Treatment as usual
University Hospital Tuebingen, German Center for Mental Health
Major Depressive Disorder
05/26
07/26
NCT03621540: Augmentation of Working Memory Training With Transcranial Direct Current Stimulation in Patients With Schizophrenia

Completed
N/A
37
Europe
active tDCS, sham tDCS, Adaptive working memory training
University Hospital Tuebingen, German Federal Ministry of Education and Research
Schizophrenia, Cognitive Deficits
12/22
05/23
de-press-2, NCT05385614: Efficacy of Gamified Cognitive Control Training Using de:)Press on Depression Severity add-on to Treatment as Usual

Recruiting
N/A
112
Europe
de:)press
University Hospital Tuebingen
Depression, Cognitive Impairment, Cognitive Dysfunction, Depressive Disorder
06/23
06/23
BOSSFRONT2, NCT06345651: Brain Oscillation-synchronized Stimulation of the Frontal Cortex in Major Depressive Disorder

Recruiting
N/A
30
Europe
Transcranial Magnetic Stimulation
University Hospital Tuebingen
Major Depressive Disorder
08/25
08/25
NCT05875194: Influence of tDCS on the Brain Activation Measured During the Decision Not to Smoke in High-risk Situations

Recruiting
N/A
60
Europe
active transcranial direct current stimulation (tDCS), sham transcranial direct current stimulation (tDCS)
University Hospital Tuebingen, NIRX Medizintechnik GmbH, Gustav-Meyer Allee 25, 13355 Berlin, Hetzler Stiftung für Suchtforschung und Prävention
Tobacco Use Disorder
10/23
12/23
NCT06130371: Stress, Inflammation and Neuroimaging in Major Depressive Disorder as Compared to Premenstrual Dysphoric Disorder

Recruiting
N/A
75
Europe
University Hospital Tuebingen
MDD, PMDD
06/25
07/25
ChangePDD, NCT04996433: A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients

Recruiting
N/A
396
Europe
inpatient CBASP individual therapy, Cognitive Behavioral Analysis System of Psychotherapy - inpatient individual therapy, inpatient CBASP group therapy, Cognitive Behavioral Analysis System of Psychotherapy - inpatient group therapy, inpatient CBASP nurse contact, Cognitive Behavioral Analysis System of Psychotherapy - inpatient nurse contact, inpatient CBASP exercise therapy, Cognitive Behavioral Analysis System of Psychotherapy - inpatient exercise therapy, outpatient CBASP group therapy, Cognitive Behavioral Analysis System of Psychotherapy - outpatient group therapy, inpatient BA individual therapy, Behavioral Activation - inpatient individual therapy, inpatient BA group therapy, Behavioral Activation - inpatient group therapy, inpatient BA nurse contact, Behavioral Activation - inpatient nurse contact, inpatient BA exercise therapy, Behavioral Activation - inpatient exercise therapy, outpatient BA group therapy, Behavioral Activation - outpatient group therapy, algorithm-based study medication, antidepressant medication
University of Greifswald, German Research Foundation, University of Kassel, University Medicine Greifswald, Charite University, Berlin, Germany, Hannover Medical School, University Hospital Lübeck, Philipps University Marburg Medical Center, Ludwig-Maximilians - University of Munich, University Hospital Tuebingen
Persistent Depressive Disorder, Treatment-resistant Depression
07/24
05/26
NCT06510985: Transcutaneous Vagus Nerve Stimulation (tVNS) for Improved Recovery After Exertion.

Not yet recruiting
N/A
120
Europe
transcutaneous vagus nerve stimulation, Monitoring, cardiowatch bracelet
University Hospital Tuebingen
Post-COVID-19 Syndrome
12/27
12/27
CARE, NCT05813080: Computer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders

Recruiting
N/A
436
Europe
"pronia.ai" medical device for high risk psychosis prognosis, Treatment-as-usual (TAU)
Heinrich-Heine University, Duesseldorf
Psychotic Disorders, Prevention
12/24
03/25
MECT-RESIST, NCT06456983: Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the Trial

Not yet recruiting
N/A
140
Europe
maintenance electroconvulsive therapy (mECT)
Central Institute of Mental Health, Mannheim
Schizophrenia, Treatment Resistant Schizophrenia
07/27
07/28
Sturm, Ekkehard
BOLD, NCT04336722 / 2019-003807-37: Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE

Active, not recruiting
3
254
Europe, Canada, US, RoW
Odevixibat, Placebo
Albireo, an Ipsen Company
Biliary Atresia
06/26
07/26
Faul, Christoph
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
NCT03853616 / 2017-002848-32: MB-CART19.1 R/r CD19+ B-cell Malignancies (BCM)

Recruiting
1/2
48
Europe
MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells
Miltenyi Biomedicine GmbH
Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory
12/24
12/24
GMALL-BLIVEN, NCT05182385: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Recruiting
1/2
39
Europe
Blinatumomab, blincyto, Venetoclax, Venclyxto
Goethe University, University Hospital Schleswig-Holstein
ALL, Recurrent, Adult
06/25
12/25
Wirths, Stefan
CLL16, NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients with High Risk CLL

Recruiting
3
650
Europe
Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence
German CLL Study Group, AstraZeneca
Chronic Lymphocytic Leukemia
05/28
05/28
FORTplus, NCT05045664: Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

Recruiting
3
100
Europe
Standard, Experimental, Rituximab, Obinutuzumab
Heidelberg University
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
12/26
12/29
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting
2
98
Europe
Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO®
Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer
Follicular Lymphoma
09/23
05/26

Download Options